Streetbeat News

Products Services

LLY

Eli Lilly has announced that it expects tight supplies of incretin products to continue while it operationalizes additional manufacturing capacity. The company anticipates that additional internal and contracted manufacturing capacity will be fully operational worldwide in the next few years.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 3:33 pm

LLY

Eli Lilly has reported acquired IPR&D charges of $2.98B for the three months ending September 30, 2023. The company is also making progress in its efforts to deliver Tirzepatide to patients outside the U.S. through different delivery presentations such as single-use vials and multi-use pens.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 3:32 pm

GOOG

GOOGL

Google is updating its AdSense program, changing the revenue-share structure and moving to paying publishers by impression rather than per click. The changes are designed to provide greater transparency and consistency for publishers. Google does not expect these changes to affect publishers' earnings. The updates are expected to go into effect early next year.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 3:11 pm

LI

Li Auto Inc's shares are trading higher by 2.3% after the company announced a 302.1% year-over-year increase in October deliveries, reaching 40,422 vehicles. The company remains the top-selling premium SUV brand in China, with anticipation building for their upcoming Li MEGA 5C BEV model.

Portfolio Pulse from Henry Khederian

November 02, 2023 | 3:03 pm

NIO

NIO Inc's shares are trading higher by 5.2% despite no company-specific news. The company recently reported its October 2023 delivery results, showing a 59.8% YoY increase with a total of 16,074 vehicles delivered. NIO's ET5T also achieved a five-star safety rating from the European New Car Assessment Programme. The company has expanded its charging infrastructure, deploying 2,079 Power Swap Stations.

Portfolio Pulse from Henry Khederian

November 02, 2023 | 3:02 pm

VIRI

Virios Therapeutics has received FDA guidance to progress IMC-1 to Phase 3 study for Fibromyalgia. Several life science companies are reviewing Phase 2 data and proposed Phase 3 program for a potential partnership. Virios has also submitted briefing materials to the FDA for a proposed investigational new drug application for IMC-2 as a treatment for Long-COVID. The company has filed for intellectual property protection for IMC-2 as treatment for LC and Alzheimer’s disease, which if granted, provides coverage to at least 2043. The company expects to have capital to support operations into Q3 of 2024.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 2:58 pm

BABA

NVDA

Chinese scientists and the Semiconductor Manufacturing International Corporation have developed a new chip, ACCEL, that outperforms Nvidia's AI chips in tasks like image recognition and autonomous driving. The ACCEL chip is not ready to replace existing chips but holds potential for integration into wearable devices, electric cars, and smart factories. This could boost China's competitiveness in AI applications and may cost Nvidia orders worth $5 billion from Alibaba.

Portfolio Pulse from Anusuya Lahiri

November 02, 2023 | 2:25 pm

MLYS

Mineralys Therapeutics (NASDAQ:MLYS) presented a new post-hoc analysis from the Target-HTN Phase 2 trial of lorundrostat, a treatment for uncontrolled or treatment-resistant hypertension. The analysis supports obesity-associated dysregulated aldosterone as an endotype predictive of enhanced response to lorundrostat treatment. The ongoing Advance-HTN trial will further characterize hypertensive endotype for enhanced response to lorundrostat treatment.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 2:05 pm

PYPL

PayPal Holdings Inc (NASDAQ:PYPL) has received a subpoena from the SEC regarding its PYUSD stablecoin, as revealed in its Q3 earnings filing. The company also received Civil Investigative Demands from the Consumer Financial Protection Bureau related to Venmo's unauthorized funds transfers and collections processes. Major exchanges have listed PYUSD on their platforms, and it was integrated into Venmo mobile payment service in September 2023. PayPal also announced a reshuffle of its top leadership management.

Portfolio Pulse from Khyathi Dalal

November 02, 2023 | 1:52 pm

BLUE

Bluebird Bio is set to present new and updated data from its gene therapy programs in sickle cell disease and beta-thalassemia at the 65th ASH Annual Meeting and Exposition. The presentation will detail efficacy, safety, and health-related quality of life data in adult and pediatric patients treated with lovo-cel and beti-cel.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 1:38 pm